Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Exclusion Criteria

• •Any chemotherapy (e.g., hydroxyurea), immunomodulatory drug therapy (e.g., thalidomide, interferon-alpha), immunosuppressive therapy, corticosteroids \> 10 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin), hormones (e.g., androgens, danazol) =\< 14 days prior to registration; note: patients who are on ruxolitinib may continue on without a 14 day wash out at the treating physician's discretion
• •Major surgery =\< 28 days or radiation =\< 6 months prior to registration
• •Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
• •Active acute infection requiring antibiotics
• •Uncontrolled congestive heart failure (New York Heart Association classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass, graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to registration
• •Participation in any study of an investigational agent (drug, biologic, device) =\< 30 days, unless during non-treatment phase
• •Any of the following:
• •* Pregnant women
• •* Nursing women
• •* Men or women of childbearing potential who are unwilling to employ adequate contraception
• •Known human immunodeficiency virus or acquired immunodeficiency syndrome-related illness
• •Clinically active hepatitis B or C
• •Active malignancy other than MF, except adequately treated basal cell carcinoma and squamous cell carcinoma of the skin, cervical carcinoma in situ or other malignancies that have been stable and off therapy for 5 years
• •Patient currently taking simvastatin, or lovastatin at a dose greater than 10 mg/day
• •Men with prostate specific antigen (PSA) \> 4 ng/ml or with uncontrolled benign prostatic hypertrophy
• •Patient received prior combination treatment with ruxolitinib and danazol together; note: previous treatment with ruxolitinib and/or danazol as single agent therapy is allowed
• •Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); use of the following strong or moderate inhibitors are prohibited =\< 7 days prior to registration
• •* Strong inhibitors of CYP3A4:
• •* Indinavir (Crixivan)
• •* Nelfinavir (Viracept)
• •* Atazanavir (Reyataz)
• •* Clarithromycin (Biaxin, Biaxin XL)
• •* Itraconazole (Sporanox)
• •* Ketoconazole (Nizoral)
• •* Nefazodone (Serzone)
• •* Saquinavir (Fortovase, Invirase)
• •* Telithromycin (Ketek)
• •* Moderate inhibitors of CYP3A4
• •* Erythromycin (Erythrocin, E.E.S., Ery-Tab, Eryc, EryPed, PCE)
• •* Fluconazole (Diflucan)
• •* Grapefruit juice
• •* Verapamil (Calan, Calan SR, Covera-HS, Isoptin SR, Verelan)
• •* Verelan PM
• •* Diltiazem (Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Taztia XT, Tiazac)